Low
₹1,390.00
High
₹1,434.90
| Previous Close | ₹1,410.40 |
|---|---|
| Day's Range | ₹1,390.00 - ₹1,434.90 |
| Open | ₹1,390.00 |
| 52 Week Range | ₹956.00 - ₹1,491.00 |
| Volume | 2,18,806 |
| Market Cap | ₹0.04 |
| Previous Close | ₹1,416.00 |
|---|---|
| Day's Range | ₹1,384.55 - ₹1,434.90 |
| Open | ₹1,384.55 |
| 52 Week Range | ₹955.20 - ₹1,490.00 |
| Volume | 1,15,904 |
| Market Cap | ₹0.04 |
| Trade Value ( ₹ in Lacs) | 3,086.04 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.04 |
| Price/Earning (TTM) | 67.44 |
| TTM EPS (₹) | 20.69 |
| P/E Ratio | 66.85 |
| Book Value(₹) | 9.09 |
| PAT Margin (%) | 13.04 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 20.50 |
| Trade Value ( ₹ in Lacs) | 1,641.20 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.04 |
| Price/Earning (TTM) | 67.44 |
| TTM EPS (₹) | 20.69 |
| P/E Ratio | 66.85 |
| Book Value(₹) | 9.09 |
| PAT Margin (%) | 13.04 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 20.50 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 10308.44 | 32041.46 |
| Expenses | N/A | N/A |
| PBT | 2081.41 | 6230.47 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1589.82 | 4615.28 |
| Founded | 2004 |
|---|---|
| Managing Director | Naresh Trehan |
| NSE Symbol | MEDANTA |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,64,271.32 | 1,942.85 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,26,842.90 | 8,500.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,85,999.88 | 4,876.30 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,23,151.56 | 8,595.00 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,20,099.46 | 1,173.00 | 835.50 - 835.50 |
| Cipla Ltd. | 1,18,071.78 | 1,461.00 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,03,549.99 | 2,261.00 | 1,875.00 - 1,875.00 |
| Lenskart Solutions Ltd. | 1,02,019.00 | 596.00 | 0.00 - 0.00 |
| Mankind Pharma Ltd. | 1,00,137.07 | 2,418.00 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 1,00,073.46 | 1,206.00 | 1,101.00 - 1,101.00 |
No Records Found
Pursuant to Regulation 30 of the Listing Regulations, Themis Medicare has informed that the Board of Directors of the Company, at its meeting held today, on Thursday, 13th August, 2026, have transacted the following business: 1. Considered and approved the Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 together with the Limited Review Reports of the Statutory Auditors, Krishaan & Co., Chartered Accountants which are attached. 2. Noted & approved the resignation of Nagraj Mogaveera as Interim Company Secretary & Compliance Officer of the Company with effect from 13th August, 2026. (Details mentioned in the attached Annexure A). 3. Considered and approved the appointment of Suresh Savaliya as Company Secretary, Compliance Officer & Key Managerial Personnel (KMP) of the Company in place of Nagraj Mogaveera with effect from 13th August, 2026. (Details mentioned in the attached Annexure B). The Board meeting commenced at 10.30 AM (IST) and concluded at 12.45 PM (IST).
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Global Health Ltd. is ₹1,410.40 as of 2026-08-13.
The market capitalisation of Global Health Ltd. is ₹37,506.27 as of 2026-08-12.
The 1-year return of Global Health Ltd. is 30.10% as of 2026-08-13.
The P/E ratio of Global Health Ltd. is 66.85 as of 2026-08-13.
The 52-week high and low of Global Health Ltd. are ₹1,491.00 and ₹956.00, respectively, as of 2026-08-13.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.